From the Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe; and Homi Bhabha National Institute, Mumbai, India.
Clin Nucl Med. 2022 Mar 1;47(3):e300-e301. doi: 10.1097/RLU.0000000000003954.
68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET/CT has evolved as the noninvasive imaging modality of choice in prostatic adenocarcinoma to detect overexpression of PSMA on prostate cancer cells. Metastasis to the thyroid gland is rarely observed in clinical practice of prostatic adenocarcinoma. Herein, we report the first and rare case of metastatic castration-resistant prostatic adenocarcinoma with thyroid metastasis. The patient demonstrated intensely PSMA-expressing primary prostatic lesion, metastatic lymph nodes, and skeletal lesions, and also mild uptake in thyroid nodule, which on further investigations was established as thyroid metastasis from prostate adenocarcinoma.
68Ga-标记的前列腺特异性膜抗原(PSMA)-11 PET/CT 已成为前列腺腺癌中检测 PSMA 在前列腺癌细胞过度表达的首选无创成像方式。在前列腺腺癌的临床实践中,甲状腺转移很少见。在此,我们报告首例罕见的转移性去势抵抗性前列腺腺癌伴甲状腺转移病例。该患者的原发性前列腺病变、转移性淋巴结和骨骼病变均表现出强烈的 PSMA 表达,甲状腺结节也有轻度摄取,进一步检查确定为前列腺腺癌的甲状腺转移。